FDA Adverse Event Injury Summary report: N

UNKNOWN EDWARDS SHEATH

MDR report key: 9355399 · Received November 21, 2019

Report

Report Number
2015691-2019-04316
Event Type
Injury
Date Received
November 21, 2019
Date of Event
March 1, 2008
Report Date
October 31, 2019
Manufacturer
EDWARDS LIFESCIENCES
Product Code
NPT
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
BE
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 0

CORRECTED DATA: F10, H6. REFERENCE CAPA-20-00141.

Additional Manufacturer Narrative · 0

THIS IS ONE OF TWELVE MANUFACTURER REPORTS BEING SUBMITTED FOR THIS CASE.  PLEASE REFERENCE RELATED MANUFACTURER REPORT NO:   2015691-2019-04314, 2015691-2019-04315, 2015691-2019-04316, 2015691-2019-04317, 2015691-2019-04318, 2015691-2019-04319, 2015691-2019-04320, 2015691-2019-04321, 2015691-2019-04322, 2015691-2019-04323, 2015691-2019-04324 AND 2015691-2019-04325.

Additional Manufacturer Narrative · 1

THIS IS ONE OF TWELVE MANUFACTURER REPORTS BEING SUBMITTED FOR THIS CASE. THE DATES OF THE EVENTS ARE UNKNOWN; HOWEVER, ACCORDING TO THE ARTICLE THE STUDY PERIOD WAS FROM 01-MAR-2008 TO 31-OCT-2011. FOR THIS REASON, THE FIRST DAY OF THE REPORTED STUDY PERIOD ((B)(6) 2008) WAS USED AS THE OCCURRENCE DATE. IN THIS CASE, THE EXACT SHEATH MODEL NUMBER IS NOT AVAILABLE. THEREFORE, THIS REPORT WILL REFLECT AN UNKNOWN EDWARDS SHEATHS. THE POSSIBLE PMA NUMBERS ASSOCIATED WITH AN EDWARDS SHEATHS ARE: K093877 -RETROFLEX 3TM INTRODUCER SHEATH SET; P110021- RETROFLEX 3 DELIVERY SYSTEM; ASCENDRA INTRODUCER SHEATH SET; P130009 - EDWARDS EXPANDABLE INTRODUCER SHEATH SET. REFERENCE ARTICLE: DUBOIS, CHRISTOPHE, ET AL. "PROSPECTIVE EVALUATION OF CLINICAL OUTCOMES IN ALL-COMER HIGH-RISK PATIENTS WITH AORTIC VALVE STENOSIS UNDERGOING MEDICAL TREATMENT, TRANSCATHETER OR SURGICAL AORTIC VALVE IMPLANTATION FOLLOWING HEART TEAM ASSESSMENT." INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY 17.3 (2013): 492-500. ACCORDING TO THE INSTRUCTIONS FOR USE (IFU), CARDIOVASCULAR COMPLICATIONS, INCLUDING PERFORATION OR DISSECTION OF VESSELS WHICH MAY REQUIRE INTERVENTION, ARE POTENTIAL ADVERSE EVENTS ASSOCIATED WITH THE TRANSFEMORAL TRANSCATHETER AORTIC VALVE REPLACEMENT PROCEDURE. ACCORDING TO LITERATURE REVIEW, AND AS DOCUMENTED IN A TECHNICAL SUMMARY WRITTEN BY EDWARDS LIFESCIENCES, VASCULAR COMPLICATIONS ARE A WELL-RECOGNIZED COMPLICATION OF THE TRANSFEMORAL TAVR PROCEDURE IN THIS ELDERLY POPULATION WITH MULTIPLE CO-MORBIDITIES. EDWARDS HAS REVIEWED MANY REPORTS, INCLUDING SCREENING DATA RECORDS AND SOURCE DOCUMENTATION OF VASCULAR COMPLICATIONS AND HAS FOUND THAT THE ROOT CAUSE IS TYPICALLY RELATED TO A COMBINATION OF VESSEL SIZE, TORTUOSITY AND CALCIFICATIONS. ALTHOUGH THE INCIDENCE IS DECREASING WITH SMALLER SHEATH/DELIVERY SYSTEM SIZES AND PHYSICIAN EXPERIENCE, THERE WILL CONTINUE TO BE CASES IN WHICH VASCULAR COMPLICATIONS WILL OCCUR.   THE THV PHYSICIAN TRAINING MANUALS INSTRUCT ON PROCEDURAL CONSIDERATIONS FOR SHEATH INSERTION WITH REGARDS TO PROPER SCREENING CRITICAL TO REDUCING VASCULAR COMPLICATIONS. THE TRAINING MANUAL INSTRUCTS THE OPERATOR ON PROPER SHEATH INSERTION AND WITHDRAWAL TECHNIQUES, INCLUDING PRE-DILATING THE VESSEL WITH THE EDWARDS DILATORS, AS NEEDED. IT ALSO NOTES THAT CALCIFICATION MAY REDUCE LUMEN DIAMETER AND LIMIT OR PREVENT TRANSFEMORAL PASSAGE OF THE DEVICES.   THE IFU CONTRAINDICATES PATIENTS WITH ILIO-FEMORAL VESSEL CHARACTERISTICS THAT WOULD PRECLUDE SAFE PLACEMENT OF SHEATHS SUCH AS SEVERE OBSTRUCTIVE CALCIFICATION OR SEVERE TORTUOSITY. PRE-PROCEDURE SCREENING AND ASSESSMENT OF THE FEMORAL/ILIAC ARTERY INTERNAL DIAMETERS WILL ENABLE THE CLINICIAN TO DETERMINE IF THE SAPIEN VALVE CAN BE DELIVERED TRANSFEMORALLY. ASSESSMENT OF LOCATION AND AMOUNT OF CIRCUMFERENTIAL CALCIUM WILL AID IN DETERMINING AREAS OF REDUCED VESSEL DIAMETERS. THE OPERATORS ARE TRAINED TO MEASURE MINIMUM VESSEL DIAMETER TAKING CALCIUM INTO ACCOUNT. THE PHYSICIAN TRAINING MANUAL ALSO LISTS THE MINIMUM RECOMMENDED VESSEL SIZE FOR EACH SIZE DEVICE.   DESPITE THE BEST SCREENING TOOLS, A SMALL PERCENTAGE OF PATIENTS WILL HAVE FEMORAL/ILIAC VESSELS THAT ARE NOT AMENABLE TO THE TRANS-FEMORAL APPROACH OR WHERE INCREASED RESISTANCE IS ENCOUNTERED DURING INSERTION OF DEVICES. IN MANY CASES, THE VESSEL MINIMUM LUMINAL DIAMETER (MLD) MAY BE BORDERLINE OR BELOW THE INDICATED SIZE. IN ADDITION, SIGNIFICANT CALCIFICATION AND/OR TORTUOSITY, NOT ALWAYS APPRECIABLE ON IMAGING, COULD BE CONTRIBUTING FACTORS TO THE EVENT.   IN THIS CASE, THERE WAS NO ALLEGATION OR INDICATION A DEVICE MALFUNCTION CONTRIBUTED TO THESE ADVERSE EVENTS.  THE ARTICLE REPORTS FOUR PATIENTS WERE OBSERVED WITH VASCULAR COMPLICATIONS, TWO OF THEM, DURING PROCEDURE. DETAILS OF THE EVENTS WERE NOT PROVIDED. THE CAUSE OF THE EVENTS IS UNKNOWN; HOWEVER, PROCEDURAL AND PATIENT FACTORS NOT PROVIDED COULD HAVE CONTRIBUTED TO THE EVENT.   THE IFU AND TRAINING MANUALS HAVE BEEN REVIEWED AND NO INADEQUACIES HAVE BEEN IDENTIFIED WITH REGARDS TO WARNINGS, CONTRAINDICATIONS, AND THE DIRECTIONS/CONDITIONS FOR THE SUCCESSFUL USE OF THE DEVICE. COMPLAINT HISTORIES FOR ALL REPORTED EVENTS ARE REVIEWED AGAINST TRENDING CONTROL LIMITS ON A MONTHLY BASIS, AND ANY EXCURSIONS ABOVE THE CONTROL LIMITS ARE ASSESSED AND DOCUMENTED AS PART OF THIS MONTHLY REVIEW. NO CORRECTIVE OR PREVENTATIVE ACTIONS ARE REQUIRED AT THIS TIME.

Description of Event or Problem · 1

AS REPORTED BY AN EDWARDS LIFESCIENCES AFFILIATE IN (B)(6), THROUGH THE REVIEW OF THE MEDICAL ARTICLE ¿PROSPECTIVE EVALUATION OF CLINICAL OUTCOMES IN ALL-COMER HIGH-RISK PATIENTS WITH AORTIC VALVE STENOSIS UNDERGOING MEDICAL TREATMENT, TRANSCATHETER OR SURGICAL AORTIC VALVE IMPLANTATION FOLLOWING HEART TEAM ASSESSMENT¿ REGARDING A GROUP OF PATIENTS WHO UNDERWENT TAVI BY TF OR TA APPROACH WITH AN EDWARDS SAPIEN VALVE OR EDWARDS SAPIEN-XT, THE FOLLOWING OUTCOMES WERE OBSERVED: - FOUR PATIENTS WERE OBSERVED WITH VASCULAR COMPLICATIONS, TWO OF THEM, DURING PROCEDURE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1149031 UNKNOWN EDWARDS SHEATH AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIVERED NPT EDWARDS LIFESCIENCES UNKNOWN EDWARDS SHEATH

Patients

Seq Age Sex Outcome Treatment
1 Other